TruBridge's Quiet Turnaround Meets a Loud Optionality: Margins Up, Leverage Down, and a Board in Play
A 34% share bounce frames a rural-hospital RCM/EHR vendor that fixed its cost base and balance sheet — and then quietly started a strategic review.
TBRG · Earnings Call · 2026-04-01
A Quiet Turnaround Behind a Loud Pivot
TruBridge ended 2025 the way it rarely has in recent memory — with the market leaning in. The rural-hospital RCM and EHR vendor, a small-cap worth roughly $389 million, capped a year of margin repair with a 34% bounce in its shares over the last 90 days. The catalyst wasn't a blowout quarter — total revenue was essentially flat at $346.8M (+1.4%) — but rather a board that finally said the quiet part out loud: it has kicked off a strategic review, withdrawn formal guidance, and announced it will "provide additional information as appropriate." For a company that has spent two years cutting costs and repairing its balance sheet, that is a big deal.
The timing is deliberate. TruBridge filed its 10-K only after an extension, citing "out-of-period adjustments" surfaced with a newly appointed external auditor — adjustments CEO Chris Fowler was careful to call "noncash and not material to our fiscal 2025 financial statements." The subtext: a genuine push toward "strengthening our financial reporting standards," a theme that matters acutely because any potential deal will put those books under a microscope.
right now, we do not have a time line on this... the Board is being super thoughtful about this... making sure that it's more about getting to the right outcome as it is about hitting a certain deadline.
The Numbers Behind the Optionality
The strategic review makes sense only because the operational turnaround is finally showing up in cash. Adjusted EBITDA rose 23% to $68.7M in 2025 with 350 basis points of margin expansion — on top of roughly 300 bps the prior year, for 650 bps across two years — and CFO Vinay Bassi guided to about 200 bps more in 2026, powered by the global offshore transition (now anchored by a new Global Capacity Center in Chennai) plus "positive ROI" cost programs. On the prior call he had telegraphed this mechanically: “200 bps is primarily from the cost optimization first... we are maniacally going to make sure it falls to the bottom line.” — Vinay Bassi, Chief Financial Officer · 2025-11-07 This time, the proof is in the statement:
free cash flow margin of 14.7%, up almost 10 points from a year ago, with free cash flow reaching $20M. The company retired about $19.5M of net debt during the year, finishing 2025 with $24.9M of cash and a net leverage ratio near 2x — the fourth straight quarter under 2.5x and a world away from the leverage position of 2023. Net debt sits at roughly $132M, and a new five-year, $250M credit facility signed in November extends the maturity wall to 2030.
Net debt was reduced to approximately $139.8 million, and our net leverage improved to 2x, marking our strongest leverage position in several years.
Top Line Still Muted, the Funnel Is Widening
The honest weakness in this quarter is the lack of top-line fuel. Q4 revenue was $87.2M, down about 1% year-over-year (roughly flat excluding the Centriq sunset), and Patient Care fell 6.6% on that sunset plus CBO attrition tied to the offshore transition. Management owns the problem: fewer renewals are in the "target" cohort, and retention is "a modest improvement to flattish improvement" as 2026 approaches. Yet every leading indicator is now pointing up. Bookings hit $19.8M TCV versus $15.5M sequentially, and the commercial engine — under a new sales leader and a regionalized coverage model — has produced a pipeline Chris Fowler calls:
“the dollar value of our overall sales pipeline is currently the highest it has been in 9 quarters and has increased 53% since the beginning of Q3.” — Christopher Fowler, President and Chief Executive Officer · 2026-04-01
The quality is improving in tandem: more than 70% of the pipeline is now recurring business, up from roughly 57% last summer, and large-hospital opportunities — 100+ beds — have grown from about 14% to 30% of the funnel, evidence the vendor is moving up-market from its critical-access core. The higher-margin encoder line is the standalone bright spot, with pipeline growth of 74% on new business and the channel ecosystem. Meanwhile, the company is betting its next margin lever on AI. The four-pillar strategy — claims-denial prediction on the financial-health side, Ambient Technology with Microsoft on the patient-care side, an AI support bot, and AI development tooling — is meant to widen both margins and stickiness. On the flagship initiative Chris was candid about the early innings: “80%, 85% of claims are going through and getting paid once they go through our edits. So now there's an opportunity for 15% of the claims to be improved.” — Christopher Fowler, President and Chief Executive Officer · 2026-04-01 That is precisely the kind of anti-attrition tool that could finally stabilize the CBO book.
Why It Matters
The market backdrop makes this a company-unique story, not a macro one. The global keyword tape is dominated by tariff refunds and energy themes — none of which touch TruBridge. Its only real macro hook is healthcare reimbursement policy, and management flagged as far back as August that clients were "absolutely heads down" modeling the $50B rural health fund from the "One Big Beautiful Bill," warning it “could have some potential headwind to the second half of the year.” — Christopher L. Fowler, President and Chief Executive Officer · 2025-08-08 That tailwind has since begun to materialize via the SAIC partnership aimed squarely at helping rural hospitals tap the fund.
So what changed, precisely? Three things: the board formally put the company in play; the cost base and balance-sheet cleanup reached the point where management can credibly claim its strongest leverage position in years; and the commercial engine flipped from volume-chasing to quality — recurring, up-market, higher-margin deals. On top of that, the AI push — from claims-denial prediction to the Ambient Technology demo at its spring client conference — gives customers (and any buyer) a reason to believe margins can keep expanding even as the top line stays muted. At 0.6x trailing revenue and about 6x free cash flow, the market is implicitly pricing a fixer-upper: price-to-FCF has compressed to barely 6x. If the strategic review ends in a sale or a merger, the optionality is enormous; if it doesn't, the company is still on a credible path to a margin step-change. Either way, holding the stock is now a bet on board discipline — and TruBridge finally looks asymmetric after years of grinding.